Publication Cover
Orbit
The International Journal on Orbital Disorders, Oculoplastic and Lacrimal Surgery
Volume 38, 2019 - Issue 5
129
Views
6
CrossRef citations to date
0
Altmetric
Original Investigation

Thiol-disulfide homeostasis as an oxidative stress marker in patients with Graves’ ophthalmopathy

, , &
Pages 370-375 | Received 02 Oct 2018, Accepted 23 Nov 2018, Published online: 18 Dec 2018

References

  • Bartalena L, Tanda ML. Clinical practice. Graves’ ophthalmopathy. N Engl J Med. 2009;360(10):994–1001. doi:10.1056/NEJMcp0806317.
  • Tsai CC, Cheng CY, Liu CY, et al. Oxidative stress in patients with Graves’ ophthalmopathy: relationship between oxidative DNA damage and clinical evolution. Eye (Lond). 2009;23(8):1725–1730. doi:10.1038/eye.2008.310.
  • Tsai CC, Wu SB, Cheng CY, et al. Increased oxidative DNA damage, lipid peroxidation, and reactive oxygen species in cultured orbital fibroblasts from patients with Graves’ ophthalmopathy: evidence that oxidative stress has a role in this disorder. Eye (Lond). 2010;24(9):1520–1525. doi:10.1038/eye.2010.31.
  • Tsai CC, Wu SB, Cheng CY, et al. Increased response to oxidative stress challenge in Graves’ ophthalmopathy orbital fibroblasts. Mol Vis. 2011;17:2782–2788.
  • Konuk O, Hondur A, Akyurek N, Unal M. Apoptosis in orbital fibroadipose tissue and its association with clinical features in Graves’ ophthalmopathy. Ocul Immunol Inflamm. 2007;15(2):105–111. doi:10.1080/09273940601186735.
  • Tsai CC, Kao SC, Cheng CY, et al. Oxidative stress change by systemic corticosteroid treatment among patients having active graves ophthalmopathy. Arch Ophthalmol. 2007;125(12):1652–1656. doi:10.1001/archopht.125.12.1652.
  • Poljsak B, Šuput D, Milisav I. Achieving the balance between ROS and antioxidants: when to use the synthetic antioxidants. Oxid Med Cell Longev. 2013;2013:956792. doi:10.1155/2013/956792.
  • Prummel MF, Bakker A, Wiersinga WM, et al. Multi-center study on the characteristics and treatment strategies of patients with Graves’ orbitopathy: the first European Group on Graves’ Orbitopathy experience. Eur J Endocrinol. 2003;148(5):491–495.
  • Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 1997;47:9–14.
  • Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest. 1991;14(10):853–860. doi:10.1007/BF03347943.
  • Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin Biochem. 2014;47(18):326–332. doi:10.1016/j.clinbiochem.2014.09.026.
  • Venditti P, Di Meo S. Thyroid hormone-induced oxidative stress. Cell Mol Life Sci. 2006;63(4):414–434. Review. doi:10.1007/s00018-005-5457-9.
  • Biswas S, Chida AS, Rahman I. Redox modifications of protein-thiols: emerging roles in cell signaling. Biochem Pharmacol. 2006;71(5):551–564. doi:10.1016/j.bcp.2005.10.044.
  • Circu ML, Aw TY. Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med. 2010;48(6):749–762. doi:10.1016/j.freeradbiomed.2009.12.022.
  • Gumusyayla S, Vural G, Bektas H, Deniz O, Neselioglu S, Erel O. A novel oxidative stress marker in patients with Alzheimer’s disease: dynamic thiol-disulphide homeostasis. Acta Neuropsychiatr. 2016;28(6):315–320. doi:10.1017/neu.2016.13.
  • Altıparmak IH, Erkuş ME, Sezen H, et al. The relation of serum thiol levels and thiol/disulphide homeostasis with the severity of coronary artery disease. Kardiol Pol. 2016;74(11):1346–1353. doi:10.5603/KP.a2016.0085.
  • Ates I, Ozkayar N, Inan B, et al. Dynamic thiol/disulphide homeostasis in patients with newly diagnosed primary hypertension. J Am Soc Hypertens. 2016;10(2):159–166. doi:10.1016/j.jash.2015.12.008.
  • Ates I, Kaplan M, Yuksel M, et al. Determination of thiol/disulphide homeostasis in type 1 diabetes mellitus and the factors associated with thiol oxidation. Endocrine. 2016;51(1):47–51. doi:10.1007/s12020-015-0784-6.
  • Heufelder AE, Wenzel BE, Bahn RS. Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves’ retroocular fibroblasts. J Clin Endocrinol Metab. 1992;74(4):737–742. doi:10.1210/jcem.74.4.1532179.
  • Rotondo Dottore G, Ionni I, Menconi F, et al. Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves’ orbitopathy (GO). J Endocrinol Invest. 2018;41(7):815–820. doi:10.1007/s40618-017-0809-5.
  • Bouzas EA, Karadimas P, Mastorakos G, Koutras DA. Antioxidant agents in the treatment of Graves’ ophthalmopathy. Am J Ophthalmol. 2000;129:618–622.
  • Marcocci C, Kahaly GJ, Krassas GE, et al. European Group on Graves’ Orbitopathy. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364(20):1920–1931. doi:10.1056/NEJMoa1012985.
  • Dharmasena A. Selenium supplementation in thyroid associated ophthalmopathy: an update. Int J Ophthalmol. 2014;7(2):365–375. doi:10.3980/j.issn.2222-3959.2014.02.31.
  • Rotondo Dottore G, Leo M, Casini G, et al. Antioxidant actions of selenium in orbital fibroblasts: a basis for the effects of selenium in Graves’ Orbitopathy. Thyroid. 2017;27(2):271–278. doi:10.1089/thy.2016.0397.
  • Koltuksuz U, Uz E, Ozen S, Aydinç M, Karaman A, Akyol O. Plasma superoxide dismutase activity and malondialdehyde level correlate with the extent of acute appendicitis. Pediatr Surg Int. 2000;16(8):559–561. doi:10.1007/s003830000424.
  • Akarsu E, Buyukhatipoglu H, Aktaran S, Kurtul N. Effects of pulse methylprednisolone and oral methylprednisolone treatments on serum levels of oxidative stress markers in Graves’ ophthalmopathy. Clin Endocrinol (Oxf). 2011;74(1):118–124. doi:10.1111/j.1365-2265.2010.03904.x.
  • Bednarek J, Wysocki H, Sowiński J. Peripheral parameters of oxidative stress in patients with infiltrative Graves’ ophthalmopathy treated with corticosteroids. Immunol Lett. 2004;93(2–3):227–232. doi:10.1016/j.imlet.2004.03.020.
  • Xing L, Ye L, Zhu W, et al. Smoking was associated with poor response to intravenous steroids therapy in Graves’ ophthalmopathy. Br J Ophthalmol. 2015;99(12):1686–1691. doi:10.1136/bjophthalmol-2014-306463.
  • Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrinol Metab. 2007 Jan;92(1):59–64. doi:10.1210/jc.2006-1824.
  • Yoon JS, Lee HJ, Chae MK, Lee SY, Lee EJ. Cigarette smoke extract-induced adipogenesis in Graves’ orbital fibroblasts is inhibited by quercetin via reduction in oxidative stress. J Endocrinol. 2013;216(2):145–156. doi:10.1530/JOE-12-0257.
  • Planck T, Shahida B, Parikh H, et al. Smoking induces overexpression of immediate early genes in active Graves’ ophthalmopathy. Thyroid. 2014;24(10):1524–1532. doi:10.1089/thy.2014.0153.
  • Kau HC, Wu SB, Tsai CC, Liu CJ, Wei YH. Cigarette smoke extract-induced oxidative stress and fibrosis-related genes expression in orbital fibroblasts from patients with Graves’ ophthalmopathy. Oxid Med Cell Longev. 2016;2016:4676289. doi:10.1155/2016/4676289.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.